Pluriomics Stem Cell technology

Pluricyte® Cardiomyocytes Validated and Optimized for Pacing using Axion BioSystems Maestro™ E-Stim+ MEA Technology

Leiden, The Netherlands, April 18th, 2017 – Pluriomics has published a new application note describing the function of electrical stimulation in Pluricyte® Cardiomyocytes by using the Maestro E-Stim+  Classic MEA plates in combination with the Maestro MEA system.

Pluriomics’ Pluricyte® Cardiomyocytes are the first hiPSC-derived cardiomyocytes being validated and optimized for pacing using Axion BioSystems’ E-Stim+ MEA technology. This new technology delivers high-quality MEA results with superior pacing capacity. Due to the robust field potential signals of Pluricyte® Cardiomyocytes and reliable artefact removal in the AxIS software, the signals are of high quality for robust detection of depolarization and repolarization peaks.

The capability to pace Pluricyte® Cardiomyocytes at user-defined beat rates enables more precise and in-depth analysis of cardioactive compound effects. As an advantage, beat rate dependent cardioactive compound effects (i.e. use-dependence) can be measured in a physiological relevant way with reduced variability from well-to-well.

Download the application note, describing the use of Pluricyte® Cardiomyocytes in the Maestro E-Stim+ Classic MEA plates for the assessment of beat-rate dependent compound effects.

Interested in using Pluricyte® Cardiomyocytes in combination with E-Stim+ plates? Please contact us at